Pictet Asset Management Holding SA Has $10.73 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Pictet Asset Management Holding SA grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 272,704 shares of the company’s stock after purchasing an additional 22,414 shares during the period. Pictet Asset Management Holding SA’s holdings in CRISPR Therapeutics were worth $10,734,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Highline Wealth Partners LLC acquired a new stake in CRISPR Therapeutics during the fourth quarter worth about $39,000. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Spire Wealth Management increased its position in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares during the period. Finally, MCF Advisors LLC bought a new position in CRISPR Therapeutics in the fourth quarter worth $80,000. Institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on CRSP shares. Truist Financial boosted their price target on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Royal Bank of Canada decreased their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 12th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Finally, Morgan Stanley boosted their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Stock Up 3.2 %

Shares of CRSP opened at $34.19 on Thursday. The stock’s fifty day simple moving average is $42.60 and its 200-day simple moving average is $44.90. The firm has a market capitalization of $2.93 billion, a PE ratio of -7.82 and a beta of 1.85. CRISPR Therapeutics AG has a 12-month low of $32.51 and a 12-month high of $67.88.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, General Counsel James R. Kasinger sold 2,850 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares of the company’s stock, valued at $3,288,822.60. This represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,381 shares of company stock valued at $1,608,243. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.